{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-23-000280","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.965390+00:00","generated_at":"2026-06-15T23:28:22.803269+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"KORU Medical Q1 revenue $7.4M (+18% YoY); reaffirms FY2023 guidance","bullets":["Q1 net revenue $7.4M, up 18% YoY; net loss $2.4M ($0.05 diluted) vs $2.5M loss prior year.","U.S. Core revenue $5.7M (+15%), International Core $1.1M (+23%), Novel Therapies $0.6M (+62%).","Gross margin 56.1% (down from 58%), but reaffirms FY margin 58-60% and exit at 60-62%.","Reaffirms FY2023 revenue guidance $32.5-33.5M (17-20% growth); cash >$10M year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-23-000280","json":"https://secwatch.observer/filing/0001161697-23-000280.json","markdown":"https://secwatch.observer/filing/0001161697-23-000280.md","text":"https://secwatch.observer/filing/0001161697-23-000280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000280/0001161697-23-000280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000280/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:28:22.803269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f578e08bcc6167400a7ee88eba5f246dfcbcef18","claim":"KORU Medical Systems, Inc. reported first quarter ended March 31, 2023 results: revenue $7.4 million, net income $2.4 million, EPS $(0.05) per diluted share. Guidance reaffirmed.","evidence_excerpt":"of life for patients, today reported financial results for the first quarter ended March 31, 2023. Highlights: ● First quarter net revenue growth versus prior year of 18% to $7.4 million, marking the sixth consecutive quarter of double-digit growth with strength in all three businesses ● U.S. Core business growth of 15% outpacing the subcutaneous immunoglobulin","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000280/0001161697-23-000280-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$7.4 million"},{"label":"Net income","value":"$2.4 million"},{"label":"EPS","value":"$(0.05) per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}